Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amplia TherapeuticsASX:ATX +14.81%27 EV-to-OCF is -5.96 as of Aug. 05, 2026. GuruFocus rates ASX:ATX with a GF Score™ of 27/100. The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, Amplia Therapeutics ranks better than 57.48% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Amplia Therapeutics's Enterprise Value is A$52.05 Mil.
Amplia Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was A$-8.73 Mil. Therefore, Amplia Therapeutics's EV-to-OCF for today is -5.96.
The historical rank and industry rank for Amplia Therapeutics's EV-to-OCF or its related term are showing as below:
ASX:ATX'
s EV-to-OCF Range Over the Past 10 Years
Min: -67.76 Med: 1.36 Max: 1.8
Current: -5.08
During the past 13 years, the highest EV-to-OCF of Amplia Therapeutics was 1.80. The lowest was -67.76. And the median was 1.36.
ASX:ATX's EV-to-OCF is ranked better than 57.48% of 1411
companies
in the Biotechnology industry
Industry Median: -3.32
vs ASX:ATX: -5.08
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Amplia Therapeutics's PE Ratio (TTM) for today is calculated as:
Amplia Therapeutics's share price for today is A$0.155.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Amplia Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was A$-0.017.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Amplia Therapeutics EV-to-OCF Related Terms
Amplia Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Amplia Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Amplia Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amplia Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Amplia Therapeutics's EV-to-OCF falls into.
Amplia Therapeutics's current Enterprise Value is A$52.05 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Amplia Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was A$-8.73 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amplia Therapeutics (ASX:ATX) has a EV-to-OCF of -5.96 as of Aug. 05, 2026. According to the industry distribution chart, Amplia Therapeutics ranks #600 out of 1411 companies in the Biotechnology industry, placing it in the top 42.5%.
Is Amplia Therapeutics' EV-to-OCF too high?
Amplia Therapeutics' current EV-to-OCF is -5.96. Based on the distribution chart, Amplia Therapeutics ranks #600 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Amplia Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Amplia Therapeutics' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Amplia Therapeutics ranks #600 out of 1411 companies for EV-to-OCF. This puts Amplia Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Amplia Therapeutics's current EV-to-OCF is -5.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplia Therapeutics stock overvalued right now?
Amplia Therapeutics (ASX:ATX) has a current EV-to-OCF of -5.96. The current EV-to-OCF is -5.96. Amplia Therapeutics' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Amplia Therapeutics (ASX:ATX), the current EV-to-OCF is -5.96 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
27GF Score
Get the complete analysis for ASX:ATX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ATX has been successfully added to your 
